SRPT - Sarepta Therapeutics Inc Stock Price, Fair Value and News

124.25USD+7.13 (+6.09%)Market Closed

Market Summary

USD124.25+7.13

Market Closed

6.09%

SRPT Stock Price

View Fullscreen

SRPT RSI Chart

SRPT Valuation

Market Cap

11.0B

Price/Earnings (Trailing)

-20.51

Price/Sales (Trailing)

8.84

EV/EBITDA

-22.98

Price/Free Cashflow

-19.05

SRPT Price/Sales (Trailing)

SRPT Profitability

EBT Margin

-41.83%

Return on Equity

-62.37%

Return on Assets

-16.42%

Free Cashflow Yield

-5.25%

SRPT Fundamentals

SRPT Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

53.54%

Rev. Growth (Qtr)

19.58%

SRPT Earnings

Earnings (TTM)

-536.0M

Earnings Growth (Yr)

141.79%

Earnings Growth (Qtr)

211.53%

Breaking Down SRPT Revenue

Last 7 days

-0.1%

Last 30 days

-8.2%

Last 90 days

-2.6%

Trailing 12 Months

-7.5%

How does SRPT drawdown profile look like?

SRPT Financial Health

Current Ratio

3.95

Debt/Equity

Debt/Cashflow

-345.51

SRPT Investor Care

Shares Dilution (1Y)

6.68%

Diluted EPS (TTM)

-5.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	975.7M	1.0B	1.1B	1.2B
2022	765.8M	835.2M	876.0M	933.0M
2021	573.4M	600.1M	645.6M	701.9M
2020	407.5M	450.2M	495.1M	540.1M
2019	323.4M	344.6M	365.1M	380.8M
2018	202.8M	241.4M	273.9M	301.0M
2017	37.9M	70.3M	102.7M	154.6M
2016	5.0M	5.2M	5.3M	5.4M
2015	0	0	0	4.9M
2014	15.8M	15.5M	12.4M	9.8M
2013	30.6M	22.3M	18.9M	14.2M
2012	43.9M	43.5M	43.6M	37.3M
2011	42.5M	50.1M	48.9M	47.0M
2010	0	21.5M	25.5M	29.4M
2009	0	0	0	17.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sarepta Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	boor kathryn jean	sold	-93,549	122	-761	-
Mar 08, 2024	rodino-klapac louise	sold (taxes)	-111,934	123	-909	head of r&d, cso
Mar 08, 2024	wigzell hans lennart rudolf	sold	-1,848,800	123	-15,000	-
Mar 08, 2024	arif bilal	sold (taxes)	-58,122	123	-472	chief tech ops officer
Mar 08, 2024	brown ryan edward	sold (taxes)	-110,703	123	-899	evp, general counsel
Mar 08, 2024	wigzell hans lennart rudolf	acquired	208,500	13.9	15,000	-
Mar 08, 2024	estepan ian michael	sold (taxes)	-127,450	123	-1,035	chief financial officer
Mar 07, 2024	rodino-klapac louise	sold (taxes)	-61,690	120	-512	head of r&d, cso
Mar 07, 2024	brown ryan edward	sold (taxes)	-60,967	120	-506	evp, general counsel
Mar 07, 2024	arif bilal	sold (taxes)	-60,967	120	-506	chief tech ops officer

Which funds bought or sold SRPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	FIFTH THIRD BANCORP	unchanged	-	33,030	129,460	-%
Apr 23, 2024	Global Retirement Partners, LLC	added	27.08	2,358	7,897	-%
Apr 23, 2024	Shepherd Financial Partners LLC	unchanged	-	124,392	487,547	0.06%
Apr 23, 2024	AMALGAMATED BANK	reduced	-67.48	-987,000	765,000	0.01%
Apr 23, 2024	Venturi Wealth Management, LLC	sold off	-100	-11,283	-	-%
Apr 23, 2024	CGC Financial Services, LLC	unchanged	-	30,156	118,197	0.06%
Apr 22, 2024	PFG Investments, LLC	added	23.66	1,240,400	3,119,340	0.19%
Apr 22, 2024	SAPIENT CAPITAL LLC	reduced	-1.29	318,163	1,296,540	0.03%
Apr 22, 2024	ALTFEST L J & CO INC	new	-	348,000	348,000	0.05%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	29.16	693,529	1,638,440	-%

Are Funds Buying or Selling SRPT?

Are funds buying SRPT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SRPT

No. of Funds

Unveiling Sarepta Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	janus henderson group plc	5.7%	5,345,785	SC 13G/A
Feb 13, 2024	vanguard group inc	9.42%	8,816,124	SC 13G/A
Feb 09, 2024	capital international investors	5.1%	4,741,485	SC 13G
Jan 26, 2024	blackrock inc.	6.7%	6,266,973	SC 13G/A
Feb 14, 2023	sands capital management, llc	2.5%	2,151,378	SC 13G/A
Feb 10, 2023	janus henderson group plc	6.9%	6,028,016	SC 13G/A
Feb 09, 2023	vanguard group inc	9.15%	8,033,264	SC 13G/A
Feb 01, 2023	blackrock inc.	6.3%	5,557,234	SC 13G/A
Feb 14, 2022	sands capital management, llc	6.16%	5,364,627	SC 13G
Feb 11, 2022	janus henderson group plc	8.3%	7,245,862	SC 13G

Recent SEC filings of Sarepta Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	S-8 POS	Employee Benefits Plan
Mar 28, 2024	S-8 POS	Employee Benefits Plan
Mar 28, 2024	S-8 POS	Employee Benefits Plan
Mar 28, 2024	S-8 POS	Employee Benefits Plan
Mar 11, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading

Peers (Alternatives to Sarepta Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Sarepta Therapeutics Inc News

Latest updates

Sarepta Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	19.6%	396,781,000	331,817,000	261,238,000	253,500,000	258,427,000	230,269,000	233,487,000	210,830,000	201,461,000	189,406,000	164,089,000	146,931,000	145,138,000	143,924,000	137,363,000	113,674,000	100,113,000	99,041,000	94,668,000	87,011,000	84,415,000
Costs and Expenses	5.5%	372,156,000	352,659,000	394,757,000	391,588,000	365,260,000	361,624,000	444,619,000	297,711,000	307,274,000	223,864,000	331,663,000	298,796,000	315,854,000	280,992,000	275,716,000	231,700,000	330,332,000	222,631,000	370,035,000	163,398,000	223,778,000
S&GA Expenses	8.9%	131,700,000	120,893,000	118,564,000	110,714,000	120,478,000	104,787,000	154,316,000	71,840,000	78,055,000	61,127,000	72,347,000	71,131,000	86,046,000	75,373,000	73,688,000	82,768,000	81,424,000	75,429,000	67,393,000	60,566,000	64,220,000
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	113,266,000	90,553,000	146,207,000
EBITDA Margin	31.9%	-0.37	-0.54	-0.81	-1.04	-0.65	-0.70	-0.48	-0.34	-0.46	-0.61	-0.93	-1.10	-	-	-	-	-	-	-	-	-
Interest Expenses	-89.1%	794,000	7,312,000	794,000	7,023,000	3,145,000	13,493,000	16,092,000	11,688,000	16,222,000	11,947,000	16,092,000	11,688,000	13,956,000	5,430,000	9,647,000	5,385,000	4,275,000	-	-	-	4,447,000
Income Taxes	-168.1%	-5,284,000	7,763,000	9,355,000	4,045,000	7,938,000	1,320,000	3,388,000	879,000	92,000	237,000	-354,000	-143,000	832,000	96,000	20,000	115,000	711,000	226,000	174,000	84,000	-779,000
Earnings Before Taxes	221.7%	40,371,000	-33,174,000	-14,585,000	-512,710,000	-101,306,000	-256,418,000	-228,093,000	-104,146,000	-121,889,000	-47,907,000	-81,759,000	-167,393,000	-188,485,000	-196,403,000	-150,800,000	-17,377,000	-234,992,000	-126,100,000	-276,229,000	-76,559,000	-141,674,000
EBT Margin	30.2%	-0.42	-0.60	-0.88	-1.13	-0.74	-0.81	-0.60	-0.46	-0.60	-0.75	-1.06	-1.23	-	-	-	-	-	-	-	-	-
Net Income	211.5%	45,655,000	-40,937,000	-23,940,000	-516,755,000	-109,244,000	-257,738,000	-231,481,000	-105,025,000	-121,981,000	-48,144,000	-81,405,000	-167,250,000	-189,317,000	-196,499,000	-150,820,000	-17,492,000	-235,703,000	-126,326,000	-276,403,000	-76,643,000	-140,895,000
Net Income Margin	31.1%	-0.43	-0.63	-0.90	-1.14	-0.75	-0.82	-0.61	-0.47	-0.60	-0.75	-1.06	-1.23	-	-	-	-	-	-	-	-	-
Free Cashflow	49.0%	-73,696,000	-144,379,000	-140,143,000	-218,881,000	-100,356,000	-73,195,000	-75,893,000	-106,726,000	-31,532,000	-133,570,000	-115,040,000	-201,520,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	5.0%	3,265	3,110	3,126	3,060	3,128	3,156	2,997	3,056	3,148	2,662	2,759	2,765	2,985	2,781	2,883	2,947	1,823	1,702	1,748	1,964	1,642
Current Assets	5.2%	2,579	2,451	2,473	2,488	2,558	2,626	2,469	2,531	2,604	2,185	2,265	2,271	2,485	2,323	2,459	2,547	1,469	1,362	1,427	1,671	1,426
Cash Equivalents	-20.9%	428	542	852	872	967	1,039	869	1,234	2,116	1,599	1,697	1,482	1,503	1,475	1,640	1,764	835	725	809	732	371
Inventory	32.3%	323	244	227	203	204	221	208	199	186	288	269	240	232	220	180	173	171	166	157	140	125
Net PPE	7.0%	227	212	189	183	180	181	183	187	191	199	203	203	190	172	153	137	130	120	117	106	97.00
Liabilities	2.6%	2,405	2,345	2,384	2,347	2,743	2,725	2,270	2,199	2,220	2,193	2,274	2,230	2,223	1,889	1,840	1,803	1,005	707	649	615	610
Current Liabilities	45.0%	654	451	499	537	620	603	546	455	453	373	425	365	416	378	355	306	265	216	162	137	174
LT Debt, Current	-	105	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	12.4%	859	764	741	713	385	431	726	857	928	470	485	535	762	892	1,043	1,145	818	995	1,099	1,349	1,032
Retained Earnings	1.0%	-4,446	-4,491	-4,450	-4,426	-3,910	-3,800	-3,543	-3,311	-3,206	-3,084	-3,036	-2,955	-2,848	-2,658	-2,462	-2,311	-2,294	-2,058	-1,931	-1,655	-1,578
Additional Paid-In Capital	0.9%	5,305	5,257	5,193	5,140	4,297	4,235	4,272	4,169	4,135	3,554	3,522	3,491	3,610	3,551	3,505	3,456	3,112	3,053	3,031	3,004	2,611
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45.00	38.00	33.00	28.00
Shares Outstanding	0.2%	94.00	94.00	93.00	93.00	88.00	87.00	87.00	87.00	81.00	80.00	80.00	80.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	10,681,686	-	-	-	6,561,646	-	-	-	6,206	-	-	-	12,576	-	-	-	11,294	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	52.4%	-54.66	-114	-122	-209	-92.39	-64.96	-66.81	-101	-29.33	-124	-109	-180	-174	-238	-107	628	-163	-67.43	-79.00	-146	-122
Share Based Compensation	-4.7%	46.00	48.00	47.00	41.00	51.00	50.00	103	29.00	30.00	27.00	29.00	29.00	30.00	27.00	28.00	24.00	22.00	21.00	20.00	16.00	13.00
Cashflow From Investing	69.4%	-64.36	-210	97.00	12.00	10.00	19.00	-289	-785	-2.58	20.00	321	157	-123	54.00	-34.22	-17.68	17.00	-17.96	152	135	-237
Cashflow From Financing	-87.4%	2.00	15.00	6.00	102	11.00	216	0.00	5.00	549	6.00	4.00	3.00	327	19.00	18.00	319	257	2.00	6.00	378	521

SRPT Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Products, net	$ 1,144,876	$ 843,769	$ 612,401
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Collaboration and other	$ 98,460	$ 89,244	$ 89,486
Total revenues	1,243,336	933,013	701,887
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)	150,343	139,989	97,049
Research and development	877,387	877,090	771,182
Selling, general and administrative	481,871	451,421	282,660
Settlement and license charges	0	0	10,000
Amortization of in-licensed rights	1,559	714	706
Total cost and expenses	1,511,160	1,469,214	1,161,597
Operating loss	(267,824)	(536,201)	(459,710)
Other (loss) income, net:
Loss on debt extinguishment	(387,329)	(125,441)	0
Gain from sale of Priority Review Voucher	102,000	0	102,000
Other income (expense), net	33,055	(28,321)	(61,238)
Total other (loss) income, net	(252,274)	(153,762)	40,762
Total	(520,098)	(689,963)	(418,948)
Income tax expense (benefit)	15,879	13,525	(168)
Net loss	(535,977)	(703,488)	(418,780)
Other comprehensive income (loss):
Unrealized gains (losses) on investments, net of tax	2,582	(1,644)	(23)
Total other comprehensive income (loss)	2,582	(1,644)	(23)
Comprehensive loss	$ (533,395)	$ (705,132)	$ (418,803)
Net loss per share - basic	$ (5.8)	$ (8.03)	$ (5.15)
Net loss per share - diluted	$ (5.8)	$ (8.03)	$ (5.15)
Weighted average number of shares of common stock used in computing basic net loss per share	92,398	87,559	81,262
Weighted average number of shares of common stock used in computing diluted net loss per share	92,398	87,559	81,262

SRPT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 428,430	$ 966,777
Short-term investments	1,247,820	1,022,597
Accounts receivable , net	400,327	214,628
Inventory	322,859	203,968
Other current assets	179,895	149,891
Total current assets	2,579,331	2,557,861
Property and equipment, net	227,154	180,037
Right of use assets	129,952	64,954
Non-current inventory	191,368	162,545
Other non-current assets	136,771	162,969
Total assets	3,264,576	3,128,366
Current liabilities:
Accounts payable	164,918	95,875
Accrued expenses	314,997	418,996
Deferred revenue, current portion	50,416	89,244
Current portion of long-term debt	105,483	0
Current portion of lease liabilities	17,845	15,489
Total current liabilities	653,659	619,604
Long-term debt	1,132,515	1,544,292
Lease liabilities, net of current portion	140,965	57,578
Deferred revenue, net of current portion	437,000	485,000
Contingent consideration	38,100	36,900
Other non-current liabilities	3,000	42
Total liabilities	2,405,239	2,743,416
Commitments and contingencies (Note 21)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding	0	0
Common stock, $0.0001 par value, 198,000,000 shares authorized; 93,731,831 and 87,950,117 issued and outstanding at December 31, 2023 and 2022, respectively	9	9
Additional paid-in capital	5,304,623	4,296,841
Accumulated other comprehensive income (loss), net of tax	918	(1,664)
Accumulated deficit	(4,446,213)	(3,910,236)
Total stockholders’ equity	859,337	384,950
Total liabilities and stockholders’ equity	$ 3,264,576	$ 3,128,366

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Douglas S. Ingram Esq.
WEBSITE	sarepta.com
INDUSTRY	Biotechnology
EMPLOYEES	1162

Sarepta Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Sarepta Therapeutics Inc? What does SRPT stand for in stocks?

SRPT is the stock ticker symbol of Sarepta Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sarepta Therapeutics Inc (SRPT)?

As of Tue Apr 23 2024, market cap of Sarepta Therapeutics Inc is 10.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRPT stock?

You can check SRPT's fair value in chart for subscribers.

What is the fair value of SRPT stock?

You can check SRPT's fair value in chart for subscribers. The fair value of Sarepta Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sarepta Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SRPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sarepta Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SRPT is over valued or under valued. Whether Sarepta Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sarepta Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRPT.

What is Sarepta Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, SRPT's PE ratio (Price to Earnings) is -20.51 and Price to Sales (PS) ratio is 8.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sarepta Therapeutics Inc's stock?

In the past 10 years, Sarepta Therapeutics Inc has provided 0.123 (multiply by 100 for percentage) rate of return.